Developing CAR T-cell therapies for solid tumors is challenging due to difficulties in finding selective cancer targets and engineering cells that require multiple targets for activation.

“Finding that balance gets harder and harder for more cancers. Right? If you start to think about pancreatic cancer or brain cancer, finding targets that if you hit the healthy pancreas or the healthy brain are not toxic, it's it's harder and harder.”